The following represents disclosure information provided by authors of this abstract. The ASCO Scientific Program Committee has reviewed all presenting author disclosure reports, identified potential conflicts of interest, and implemented strategies to manage those areas of conflict, where appropriate. All relationships are considered self-held and compensated unless otherwise noted. Employment/Leadership relationships are considered compensated employment unless otherwise noted. L = Leadership, U = Uncompensated, I = Immediate Family Member, B = Both Myself and Immediate Family Member, Inst = My Institution
Phase II study of bevacizumab (Bv) in combination with paclitaxel-carboplatin (PC) as first-line chemotherapy for nonsquamous (SQ) non-small cell lung cancer (NSCLC) with malignant pleural effusion (MPE).
Motohiro Tamiya
No relevant relationships to disclose
Tomonori Hirashima
No relevant relationships to disclose
Akihiro Tamiya
No relevant relationships to disclose
Norio Okamoto
No relevant relationships to disclose
Hidekazu Suzuki
No relevant relationships to disclose
Tadahiro Yamadori
No relevant relationships to disclose
Naoko Morishita
No relevant relationships to disclose
Takayuki Shiroyama
No relevant relationships to disclose
Tomoyuki Otsuka
No relevant relationships to disclose
Kanako Kitai
No relevant relationships to disclose
Tomomi Yasue
No relevant relationships to disclose
Kazuhiro Asami
No relevant relationships to disclose
Shojiro Minomo
No relevant relationships to disclose
Syoko Sonobe
No relevant relationships to disclose
Keiko Nakao
No relevant relationships to disclose
Tomoya Kawaguchi
No relevant relationships to disclose
Shinji Atagi
No relevant relationships to disclose
Ichiro Kawase
No relevant relationships to disclose